IP Library Granted Patent US 10,300,130
Granted Patent B2
US 10,300,130 · App. 15/223,980 · Granted May 28, 2019

Cytomegalovirus vaccines and methods of production

Inventors: Thomas Shenk (Princeton, NJ); Dai Wang (Blue Bell, PA)
Assignee: The Trustees of Princeton University
A61K39/245A61K39/12C12N7/00A61K2039/5252A61K2039/5254A61K2039/54C12N2710/16134C12N2710/16151C12N2710/16164
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,300,130
App. No.
15/223,980
Granted
May 28, 2019
Kind
B2
Abstract

Methods of increasing diversity in cytomegalovirus vaccines through the selection of cell type in which the virus is propagated, and the use of cytomegalovirus produced by those methods in the development of vaccine compositions, are disclosed. Vaccine compositions comprising CMV isolated from epithelial cells are also disclosed.

Claims (12)

1. A method of making an immunogenic composition comprising a population of live attenuated, inactivated or killed cytomegaloviruses (CMVs), or virion components thereof, comprising:

a) passaging a single strain or isolate of CMV having a gene encoding a functional pUL131 protein in a fibroblast cell culture to thereby produce a passaged strain or isolate of CMV;

b) amplifying the passaged strain or isolate of CMV in an epithelial cell culture to thereby produce an amplified strain or isolate of CMV;

c) harvesting the amplified strain or isolate of CMV from the epithelial cell culture to thereby obtain cell-type conditioned CMV; and

d) combining the cell-type conditioned CMV with a pharmaceutically acceptable adjuvant,

thereby making an immunogenic composition comprising a population live attenuated, inactivated or killed CMVs, or virion components thereof.

2. The method of claim 1 , wherein the passaged strain or isolate of CMV is amplified in a single epithelial cell culture.

3. The method of claim 1 , wherein the passaged strain or isolate of CMV is amplified in two or more different epithelial cell cultures.

4. The method of claim 1 , wherein the single strain or isolate of CMV is a human CMV strain or isolate.

5. The method of claim 1 , wherein the single strain or isolate of CMV is an unmodified CMV strain or isolate, or a chimeric CMV strain or isolate.

6. The method of claim 1 , wherein the immunogenic composition comprises a population live attenuated CMVs, or virion components thereof.

7. The method of claim 1 , wherein the immunogenic composition comprises a population of inactivated or killed CMVs, or virion components thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2017
From: SHENK, THOMAS; WANG, DAI
To: THE TRUSTEES OF PRINCETON UNIVERSITY
Reel/Frame 041461/0126 →
CONFIRMATORY LICENSE Recorded Oct 5, 2016
From: PRINCETON UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 040225/0773 →
Continuity (3)
Continuation 12681504
Provisional Application 60998426 · Oct 10, 2007
Related Publication 20170014504A1 · Jan 19, 2017